Murphy Middleton Hinkle & Parker’s AbbVie ABBV Stock Holding History

Murphy Middleton Hinkle & Parker’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410K	Hold	1,630	–	–	0.17%	107
2026 Q1	$355K	Buy	+1,630	New	+$362K	0.16%	107
2025 Q4	–	Sell	-1,592	Closed	-$369K	–	135
2025 Q3	$369K	Hold	1,592	–	–	0.18%	106
2025 Q2	$334K	Hold	1,592	–	–	0.19%	106
2025 Q1	$334K	Hold	1,592	–	–	0.19%	106
2024 Q4	$283K	Hold	1,592	–	–	0.16%	114
2024 Q3	$314K	Hold	1,592	–	–	0.17%	114
2024 Q2	$273K	Hold	1,592	–	–	0.16%	117
2024 Q1	$290K	Hold	1,592	–	–	0.17%	117
2023 Q4	$247K	Hold	1,592	–	–	0.15%	122
2023 Q3	$237K	Hold	1,592	–	–	0.15%	127
2023 Q2	$214K	Hold	1,592	–	–	0.13%	130
2023 Q1	$254K	Sell	1,592 -81	-5%	-$12.4K	0.16%	122
2022 Q4	$270K	Hold	1,673	–	–	0.17%	119
2022 Q3	$224K	Buy	1,673 +1	+0.1%	+$143	0.16%	118
2022 Q2	$256K	Buy	1,672 +1	+0.1%	+$153	0.17%	118
2022 Q1	$271K	Buy	1,671 +1	+0.1%	+$145	0.15%	125
2021 Q4	$226K	Buy	+1,670	New	+$197K	0.12%	137

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Murphy Middleton Hinkle & Parker's ABBV Position: Q2 2026 in Review

Murphy Middleton Hinkle & Parker held its AbbVie (ABBV) position steady in Q2 2026 at 1,630 shares worth $410K. The position accounts for 0.17% of the portfolio, ranked #107.

Murphy Middleton Hinkle & Parker first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. 921 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Murphy Middleton Hinkle & Parker held 1,630 shares of AbbVie worth $410K as of Q2 2026.
Murphy Middleton Hinkle & Parker left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.17% of Murphy Middleton Hinkle & Parker's portfolio in Q2 2026, its #107 holding.
Murphy Middleton Hinkle & Parker first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
921 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Murphy Middleton Hinkle & Parker's 13F filing for Q2 2026, filed 14 Jul 2026.